fbpx

Understanding: Videos and Talks

Develop Your Understanding​

Listen to these pioneering discussions to hear more about the potential of psychedelic medicines.

60 Minutes Australia

A novel drug trial could see ecstasy used as prescription medicine for those living with PTSD and mental illness.

See the results of a world-leading trial into MDMA-assisted psychotherapy.

Psychedelics Create New Communication Pathways In The Brain ( Homological Scaffolds )

Beckley Foundation

Watch our brains become more connected on psilocybin, and learn how psychedelics can help treat conditions such as depression, addiction, and PTSD.

Roland R. Griffiths, Ph.D - Johns Hopkins

The science of psilocybin and its use to relieve suffering

Leading psychopharmacologist Dr Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.

Sam Harris - Neuroscientist

Sam describes his most recent mushroom trip

Sam reflects on his most recent psychedelic experience.

Rick Doblin. Ph.D - Executive Director of MAPS

The Promise of Psychedelics for PTSD - Oslo Freedom Forum

Rick Doblin has committed his life to researching the use of psychedelics and marijuana to treat post-traumatic stress disorder (PTSD). Conventional treatments like anti-depressants are only effective for 40-60% of patients suffering from PTSD. Doblin explains the  toll the disorder takes on the human rights community, and recent developments that will embolden research into alternative treatments.

Robin Carhart-Harris Ph.D - Imperial College London

Psychedelics: Lifting the veil

Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment. After completing his PhD at the University of Bristol in 2009, Robin moved to Imperial College London, where he has worked for the last few years on the brain effects of LSD, psilocybin (magic mushrooms) and MDMA, conducting some pioneering brain imaging studies of these drugs. Most recently he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat major depression.

Mind Medicine Australia Conversation - Trip of Compassion - Sydney

The following is a recording of a panel after our screening of Israeli documentary, Trip of Compassion in Sydney. Trip of Compassion is an acclaimed documentary on MDMA-assisted psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). Trip of Compassion follows several patients participating in clinical trials in Israel and is the first feature documentary to show footage from within psychedelic-assisted therapy sessions.
 
Our Executive Director, Tania de Jong AM, guided the panel through a great discussion of the science, ethics, policy and therapeutic potential of medicinal MDMA and psilocybin. On the panel we had Chair of Mind Medicine Australia, Peter Hunt AM, Executive Director of the Ethics centre Dr Simon Longstaff AO, The Hon. Andrew Robb AO former Federal Minister of the Liberal party, and our Education and Communication officer Melissa Warner.

Trip of Compassion

"The Most Compelling Movie I’ve Seen In The Last Year

“I first watched “Trip of Compassion” about six months ago, when I was sent a link to a private video. The film had been broadcast once on Israeli television, but it wasn’t distributed or available anywhere else. This documentary affected me so deeply (and immediately) that I flew to Tel Aviv, met the filmmakers, and offered to help launch the film digitally worldwide. Everything I am doing for this film is 100% pro bono, and all proceeds go to the filmmakers.” – Tim Ferris

Stephen Bright Ph.D - Vice President of PRISM ​

The Psychedelic Renaissance

Psychedelic drugs: a dangerous and illegal scourge; a harmless way to “turn on, tune in, drop out” – or a valuable treatment for mental illness? Research is showing that substances like MDMA and magic mushrooms, long banished to society’s fringes, are proving effective in treating everything from PTSD to nicotine addiction. In this talk, Stephen Bright explores the recent re-emergence of psychedelic science and discusses why this field is absent from the Australian research landscape. Dr Stephen Bright is a clinically-trained psychologist. He is a Senior Lecturer of Addiction at Edith Cowan University in Perth and a founding board member of PRISM, an Australian not-for-profit set up to advance the cause of psychedelic research.

Melissa Warner, CEO of Mind Medicine Australia

A Message from our Education and Communications Officer

Innovating Mind: Why Australia needs a psychedelic research program From FastSmarts: Innovator of the Year by VESKI for Melbourne Knowledge Week 2018
Close Menu